Subsequent Events	6 Months Ended
Jun. 30, 2025
Subsequent Events
Subsequent Events	11. Subsequent Events Entry into Share Purchase Agreement with XOMA On August 3, 2025, the Company entered into a share purchase agreement with XOMA Royalty Corporation, a Nevada corporation (“XOMA”). The purchase agreement (the “Purchase Agreement”) provides for, among other things, the acquisition of all of the Company’s issued and outstanding common shares, par value €0.12 per share, by XOMA through a tender offer, for a price per share of $1.16 plus an additional amount of cash of up to $0.08 per share plus one contingent value right per share, which represents the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, a contingent value rights agreement. If the Purchase Agreement is terminated by the Company under certain circumstances specified in the Purchase Agreement, including in connection wih the Company’s entry into an agreement with respect to a Superior Proposal (as such term is defined in the Purchase Agreement), the Company would be required to pay XOMA a termination fee of $0.75 million. Decision to Discontinue Phase 1 Trial of LAVA-1266 On August 4, 2025, the Company announced its decision to discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome and initiate the wind-down of the LAVA-1266 program. An estimate of costs related to the discontinuance of the LAVA-1266 clinical trial cannot be made at this time.

Subsequent Events

6 Months Ended

Jun. 30, 2025

11. Subsequent Events

Entry into Share Purchase Agreement with XOMA

On August 3, 2025, the Company entered into a share purchase agreement with XOMA Royalty Corporation, a Nevada corporation (“XOMA”). The purchase agreement (the “Purchase Agreement”) provides for, among other things, the acquisition of all of the Company’s issued and outstanding common shares, par value €0.12 per share, by XOMA through a tender offer, for a price per share of $1.16 plus an additional amount of cash of up to $0.08 per share plus one contingent value right per share, which represents the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, a contingent value rights agreement.

If the Purchase Agreement is terminated by the Company under certain circumstances specified in the Purchase Agreement, including in connection wih the Company’s entry into an agreement with respect to a Superior Proposal (as such term is defined in the Purchase Agreement), the Company would be required to pay XOMA a termination fee of $0.75 million.

Decision to Discontinue Phase 1 Trial of LAVA-1266

On August 4, 2025, the Company announced its decision to discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome and initiate the wind-down of the LAVA-1266 program. An estimate of costs related to the discontinuance of the LAVA-1266 clinical trial cannot be made at this time.

LAVA Therapeutics NV 10-Q